PL1835937T3 - Kompozycje i sposoby leczenia infekcji wirusowej - Google Patents
Kompozycje i sposoby leczenia infekcji wirusowejInfo
- Publication number
- PL1835937T3 PL1835937T3 PL06700714T PL06700714T PL1835937T3 PL 1835937 T3 PL1835937 T3 PL 1835937T3 PL 06700714 T PL06700714 T PL 06700714T PL 06700714 T PL06700714 T PL 06700714T PL 1835937 T3 PL1835937 T3 PL 1835937T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- treating viral
- compositions
- viral infection
- receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500027 | 2005-01-06 | ||
PCT/EP2006/050071 WO2006072624A2 (en) | 2005-01-06 | 2006-01-06 | Compositions and methods for treating viral infection |
EP06700714A EP1835937B1 (en) | 2005-01-06 | 2006-01-06 | Compositions and methods for treating viral infection |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1835937T3 true PL1835937T3 (pl) | 2012-09-28 |
Family
ID=36593628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06700714T PL1835937T3 (pl) | 2005-01-06 | 2006-01-06 | Kompozycje i sposoby leczenia infekcji wirusowej |
Country Status (11)
Country | Link |
---|---|
US (2) | US8551483B2 (pl) |
EP (1) | EP1835937B1 (pl) |
JP (1) | JP5154949B2 (pl) |
AT (1) | ATE552852T1 (pl) |
CY (1) | CY1113182T1 (pl) |
DK (1) | DK1835937T3 (pl) |
ES (1) | ES2384466T3 (pl) |
PL (1) | PL1835937T3 (pl) |
PT (1) | PT1835937E (pl) |
SI (1) | SI1835937T1 (pl) |
WO (1) | WO2006072624A2 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
MXPA05013923A (es) | 2003-07-02 | 2006-08-11 | Univ Genova | Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia. |
AU2005259221B2 (en) * | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US20110280849A1 (en) * | 2010-03-26 | 2011-11-17 | Anthrogenesis Corporation | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
CN103717619B (zh) * | 2011-05-25 | 2018-11-13 | 因内特制药股份有限公司 | 治疗发炎及自体免疫疾病之抗-kir抗体 |
JPWO2014189138A1 (ja) * | 2013-05-23 | 2017-02-23 | Idacセラノスティクス株式会社 | 免疫不全ウイルス感染の治療又は予防剤 |
KR102298172B1 (ko) | 2013-09-06 | 2021-09-06 | 아카데미아 시니카 | 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화 |
KR20220151036A (ko) | 2014-05-27 | 2022-11-11 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
EP3149045B1 (en) * | 2014-05-27 | 2023-01-18 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
WO2015184002A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
WO2015184001A1 (en) | 2014-05-28 | 2015-12-03 | Academia Sinica | Anti-tnf-alpha glycoantibodies and uses thereof |
EP3187583B1 (en) * | 2014-08-29 | 2023-04-26 | National University Corporation Hokkaido University | Monoclonal antibody against kir2ds1 |
WO2017159088A1 (ja) * | 2016-03-16 | 2017-09-21 | 国立大学法人京都大学 | 移植用培養細胞または培養組織の調製方法 |
US10858431B2 (en) * | 2016-06-30 | 2020-12-08 | Trellis Bioscience, Llc | Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling |
TWI764917B (zh) | 2016-08-22 | 2022-05-21 | 醣基生醫股份有限公司 | 抗體、結合片段及使用方法 |
US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
CN109833480B (zh) * | 2019-03-22 | 2021-09-07 | 中国科学院上海巴斯德研究所 | 靶向nk细胞免疫检查点治疗感染性疾病的方法 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
US5583034A (en) | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
US5808028A (en) | 1994-05-24 | 1998-09-15 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clone of a P58 receptor protein and uses thereof |
EP1179541B1 (en) | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
MXPA05013923A (es) | 2003-07-02 | 2006-08-11 | Univ Genova | Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia. |
PT1648507T (pt) | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
-
2006
- 2006-01-06 PT PT06700714T patent/PT1835937E/pt unknown
- 2006-01-06 US US11/813,399 patent/US8551483B2/en active Active
- 2006-01-06 AT AT06700714T patent/ATE552852T1/de active
- 2006-01-06 DK DK06700714.6T patent/DK1835937T3/da active
- 2006-01-06 SI SI200631360T patent/SI1835937T1/sl unknown
- 2006-01-06 WO PCT/EP2006/050071 patent/WO2006072624A2/en active Application Filing
- 2006-01-06 PL PL06700714T patent/PL1835937T3/pl unknown
- 2006-01-06 JP JP2007549894A patent/JP5154949B2/ja active Active
- 2006-01-06 ES ES06700714T patent/ES2384466T3/es active Active
- 2006-01-06 EP EP06700714A patent/EP1835937B1/en active Active
-
2012
- 2012-06-29 CY CY20121100586T patent/CY1113182T1/el unknown
-
2013
- 2013-10-01 US US14/043,402 patent/US9333255B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SI1835937T1 (sl) | 2012-08-31 |
JP5154949B2 (ja) | 2013-02-27 |
ATE552852T1 (de) | 2012-04-15 |
US20140023646A1 (en) | 2014-01-23 |
US20090035305A1 (en) | 2009-02-05 |
CY1113182T1 (el) | 2016-04-13 |
ES2384466T3 (es) | 2012-07-05 |
DK1835937T3 (da) | 2012-07-23 |
JP2008526812A (ja) | 2008-07-24 |
US9333255B2 (en) | 2016-05-10 |
EP1835937A2 (en) | 2007-09-26 |
EP1835937B1 (en) | 2012-04-11 |
WO2006072624A2 (en) | 2006-07-13 |
PT1835937E (pt) | 2012-06-25 |
US8551483B2 (en) | 2013-10-08 |
WO2006072624A3 (en) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1835937T1 (sl) | Sestavki in postopki za zdravljenje virusne infekcije | |
NO341586B1 (no) | Fremgangsmåte for valg av et anti-naturlig drepe cellereseptor (NKR) antistoff | |
DK1578936T3 (da) | Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen | |
BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
WO2006110814A3 (en) | Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | |
BR0212469A (pt) | Método para multiplicação de vìrus em cultura de célula | |
TW200630093A (en) | Dose forms | |
EA201000424A1 (ru) | Антитела к il-23 | |
ATE503769T1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
WO2010034670A3 (en) | Host cell kinases as targets for antiviral therapies against hcv infection | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
WO2004113277A3 (en) | Methods and compositions for treating amyloid-related diseases | |
IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
DE602006019977D1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
NO20070854L (no) | Humane monoklonale antistoffer mot humant IL-4. | |
WO2010047830A3 (en) | Agents for hcv treatment | |
EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
WO2006137938A3 (en) | Antibody fragments for protection from pathogen infection and methods of use thereof | |
WO2002092013A3 (en) | Methods for treating liver disease and liver damage with growth hormone and foxm1b | |
WO2006116185A3 (en) | Methods for the treatment of multiple myeloma | |
CL2007002370A1 (es) | Conjugado que consta de un anticuerpo anti-ccr5 y uno o mas peptidos antifusogenicos; composicion farmaceutica que lo comprende; metodo de preparacion; y su uso para tratar infecciones virales. | |
AR055072A1 (es) | Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical | |
WO2008063996A3 (en) | Therapeutic targeting of escort proteins | |
WO2006055404A3 (en) | Compounds for targeting mechanisms implicated in the progression of stroke |